News articles about Novartis AG (NYSE:NVS) have trended positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis AG earned a news impact score of 0.27 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.9114858432951 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment’s analysis:

A number of brokerages recently commented on NVS. Morgan Stanley reaffirmed a “sell” rating on shares of Novartis AG in a research report on Tuesday, June 6th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research report on Thursday, June 8th. Barclays PLC upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research report on Thursday, June 22nd. Leerink Swann reissued a “market perform” rating and set a $83.00 target price on shares of Novartis AG in a research note on Thursday, June 22nd. Finally, Credit Suisse Group lowered shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price for the company. in a research note on Wednesday, July 5th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the company’s stock. Novartis AG currently has an average rating of “Hold” and an average price target of $85.12.

Novartis AG (NVS) traded up 0.36% during midday trading on Tuesday, hitting $86.65. 2,600,992 shares of the company traded hands. The stock’s 50-day moving average is $84.67 and its 200-day moving average is $81.25. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The firm has a market capitalization of $203.01 billion, a PE ratio of 31.64 and a beta of 0.73.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. During the same period last year, the company earned $1.23 earnings per share. Novartis AG’s quarterly revenue was down 1.8% on a year-over-year basis. Analysts anticipate that Novartis AG will post $4.75 EPS for the current fiscal year.

In other Novartis AG news, major shareholder Bioventures Ltd Novartis purchased 266,667 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was bought at an average cost of $15.00 per share, with a total value of $4,000,005.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.01% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Insider Buying and Selling by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.